基于雷帕霉素和PTCy预防方案的曼哈顿风险预测急性移植物抗宿主病严重程度的验证：对459例连续造血干细胞移植患者的研究 - Suppr | 超能文献

相似文献

1

Validation of Manhattan risk to predict aGvHD severity in Rapamycin and PTCy-based prophylaxis: a study on 459 consecutive HCT patients.基于雷帕霉素和PTCy预防方案的曼哈顿风险预测急性移植物抗宿主病严重程度的验证：对459例连续造血干细胞移植患者的研究

Bone Marrow Transplant. 2025 Jul 21. doi: 10.1038/s41409-025-02677-0.

2

Treatment-Responsive Acute Graft-versus-Host Disease after Post-Transplantation Cyclophosphamide-Based Prophylaxis: Incidence and Clinical Outcomes.移植后环磷酰胺预防治疗后发生的治疗反应性急性移植物抗宿主病：发生率和临床结局。

Transplant Cell Ther. 2024 Jul;30(7):688.e1-688.e9. doi: 10.1016/j.jtct.2024.05.007. Epub 2024 May 9.

3

Mycophenolate Mofetil: A Friend or a Foe with Post-Transplantation Cyclophosphamide and Tacrolimus Prophylaxis in HLA-Matched Donors?霉酚酸酯：与 HLA 匹配供体的移植后环磷酰胺和他克莫司预防一起是朋友还是敌人？

Transplant Cell Ther. 2022 Aug;28(8):500.e1-500.e10. doi: 10.1016/j.jtct.2022.05.039. Epub 2022 May 31.

4

Redefining Engraftment Syndrome After Post-Transplant Cyclophosphamide Allogeneic Hematopoietic Cell Transplantation: A Novel Classification and Impact on Outcomes.

Transplant Cell Ther. 2025 Jun 7. doi: 10.1016/j.jtct.2025.06.003.

5

Association of Cyclosporine Exposure Post-Allogeneic Hematopoietic Cell Transplant With Graft Failure and Relapse Risk in Hematological Malignancies.

Transplant Cell Ther. 2025 Sep;31(9):695.e1-695.e12. doi: 10.1016/j.jtct.2025.05.024. Epub 2025 Jun 11.

6

Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.造血细胞移植和细胞治疗的当前活动趋势与结果——来自CIBMTR的报告

Transplant Cell Ther. 2025 May 19. doi: 10.1016/j.jtct.2025.05.014.

7

Superior GVHD-Free, Relapse-Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.欧洲血液与骨髓移植学会急性白血病工作组的一项研究：对于处于第二次完全缓解期接受移植的急性髓系白血病患者，单倍体相合移植联合环磷酰胺后在无移植物抗宿主病、无复发存活方面优于匹配无关供体移植。

Am J Hematol. 2025 Oct;100(10):1760-1771. doi: 10.1002/ajh.70008. Epub 2025 Jul 12.

8

Comparison of Chimerism Kinetics and Associated Outcomes in Patients Receiving Post-Transplant Cyclophosphamide Versus Methotrexate based GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplant.接受移植后环磷酰胺与基于甲氨蝶呤的移植物抗宿主病预防方案的异基因造血细胞移植患者的嵌合动力学及相关结果比较

Transplant Cell Ther. 2025 Sep;31(9):670.e1-670.e11. doi: 10.1016/j.jtct.2025.05.006. Epub 2025 May 16.

9

Low-dose anti-thymocyte globulin combined with low-dose post-transplant cyclophosphamide: a novel approach to prevent graft-versus-host disease in haploidentical stem cell transplantation.低剂量抗胸腺细胞球蛋白联合低剂量移植后环磷酰胺：预防单倍体干细胞移植中移植物抗宿主病的新方法。

Ther Adv Hematol. 2025 Jul 8;16:20406207251353011. doi: 10.1177/20406207251353011. eCollection 2025.

10

Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation.移植后中等剂量环磷酰胺用于清髓性HLA单倍型相合骨髓移植

Blood Adv. 2025 May 27;9(10):2553-2569. doi: 10.1182/bloodadvances.2024014879.

本文引用的文献

1

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.新型 MAGIC 综合评分结合临床症状和生物标志物，可更好地预测急性移植物抗宿主病的治疗效果。

Blood. 2024 Aug 29;144(9):1010-1021. doi: 10.1182/blood.2024025106.

2

ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?在异基因造血干细胞移植中，使用抗胸腺细胞球蛋白或移植后环磷酰胺来预防移植物抗宿主病？

Leukemia. 2024 May;38(5):1156-1163. doi: 10.1038/s41375-024-02225-7. Epub 2024 Mar 27.

3

Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.